Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

  • Young-Su Yi (Department of Life Sciences, Kyonggi University)
  • Received : 2023.06.27
  • Accepted : 2023.11.10
  • Published : 2024.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by hepatic fat accumulation, while nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD characterized by hepatic inflammation, fibrosis, and liver injury, resulting in liver cirrhosis and hepatocellular carcinoma (HCC). Given the evidence that ginseng and its major bioactive components, ginsenosides, have potent anti-adipogenic, anti-inflammatory, anti-oxidative, and anti-fibrogenic effects, the pharmacological effect of ginseng and ginsenosides on NAFLD and NASH is noteworthy. Furthermore, numerous studies have successfully demonstrated the protective effect of ginseng on these diseases, as well as the underlying mechanisms in animal disease models and cells, such as hepatocytes and macrophages. This review discusses recent studies that explore the pharmacological roles of ginseng and ginsenosides in NAFLD and NASH and highlights their potential as agents to prevent and treat NAFLD, NASH, and liver diseases caused by hepatic steatosis and inflammation.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (RS-2023-00239222).

References

  1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397(10290):2212-24. https://doi.org/10.1016/S0140-6736(20)32511-3
  2. Bacon BR, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107(4):1103-9. https://doi.org/10.1016/0016-5085(94)90235-6
  3. Khan RS, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 2019;70(2):711-24. https://doi.org/10.1002/hep.30429
  4. Yang KC, et al. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci Rep 2016;6:27034.
  5. Iacob SA, Iacob DG. Non-alcoholic fatty liver disease in HIV/HBV patients - a metabolic imbalance aggravated by antiretroviral therapy and perpetuated by the hepatokine/adipokine Axis breakdown. Front Endocrinol (Lausanne) 2022;13:814209.
  6. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 2015;13(12):2062-70. https://doi.org/10.1016/j.cgh.2015.07.029
  7. Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 2016;150(8):1769-77. https://doi.org/10.1053/j.gastro.2016.02.066
  8. Zheng Q, et al. Comparison of animal models for the study of nonalcoholic fatty liver disease. Lab Invest 2023;103(7):100129.
  9. Jadhav K, Cohen TS. Can you trust your gut? Implicating a disrupted intestinal microbiome in the progression of NAFLD/NASH. Front Endocrinol (Lausanne) 2020;11:592157.
  10. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7(3):293-302. https://doi.org/10.2174/157016109788340767
  11. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58(11):1685-93. https://doi.org/10.1016/S0006-2952(99)00212-9
  12. Ratan ZA, et al. Pharmacological potential of ginseng and its major component ginsenosides. J Ginseng Res 2021;45(2):199-210. https://doi.org/10.1016/j.jgr.2020.02.004
  13. Zhao F, Lu M, Wang H. Ginsenoside Rg1 ameliorates chronic intermittent hypoxia-induced vascular endothelial dysfunction by suppressing the formation of mitochondrial reactive oxygen species through the calpain-1 pathway. J Ginseng Res 2023;47(1):144-54. https://doi.org/10.1016/j.jgr.2022.07.006
  14. Cho HJ, Kim E, Yi YS. Korean red ginseng saponins play an anti-inflammatory role by targeting caspase-11 non-canonical inflammasome in macrophages. Int J Mol Sci 2023;24(2).
  15. Yi YS. Potential benefits of ginseng against COVID-19 by targeting inflammasomes. J Ginseng Res 2022;46(6):722-30. https://doi.org/10.1016/j.jgr.2022.03.008
  16. Min JH, Cho HJ, Yi YS. A novel mechanism of Korean Red Ginseng-mediated anti-inflammatory action via targeting caspase-11 non-canonical inflammasome in macrophages. J Ginseng Res 2022;46(5):675-82. https://doi.org/10.1016/j.jgr.2021.12.009
  17. Yi YS. New mechanisms of ginseng saponin-mediated anti-inflammatory action via targeting canonical inflammasome signaling pathways. J Ethnopharmacol 2021;278:114292.
  18. Huang Q, et al. Review of ginsenosides targeting mitochondrial function to treat multiple disorders: current status and perspectives. J Ginseng Res 2021;45(3):371-9. https://doi.org/10.1016/j.jgr.2020.12.004
  19. Shi ZY, Zeng JZ, Wong AST. Chemical structures and pharmacological profiles of ginseng saponins. Molecules 2019;24(13).
  20. Nguyen NH, Nguyen CT. Pharmacological effects of ginseng on infectious diseases. Inflammopharmacology 2019;27(5):871-83. https://doi.org/10.1007/s10787-019-00630-4
  21. Li Z, Ji GE. Ginseng and obesity. J Ginseng Res 2018;42(1):1-8. https://doi.org/10.1016/j.jgr.2016.12.005
  22. Aminifard T, Razavi BM, Hosseinzadeh H. The effects of ginseng on the metabolic syndrome: an updated review. Food Sci Nutr 2021;9(9):5293-311. https://doi.org/10.1002/fsn3.2475
  23. Hong SH, et al. Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat. Food Chem Toxicol 2013;55:586-91. https://doi.org/10.1016/j.fct.2013.01.022
  24. Bahr I, et al. Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol 2020;11:245.
  25. Hong JT, et al. Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function. J Ginseng Res 2021;45(2):316-24. https://doi.org/10.1016/j.jgr.2020.07.004
  26. Xu Y, et al. Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. Hepatol Int 2021;15(2):350-65. https://doi.org/10.1007/s12072-021-10138-1
  27. Park M, et al. Ameliorative effects of black ginseng on nonalcoholic fatty liver disease in free fatty acid-induced HepG2 cells and high-fat/high-fructose diet-fed mice. J Ginseng Res 2020;44(2):350-61. https://doi.org/10.1016/j.jgr.2019.09.004
  28. Wang F, et al. Ginseng saponin enriched in Rh1 and Rg2 ameliorates nonalcoholic fatty liver disease by inhibiting inflammasome activation. Nutrients 2021;13(3).
  29. Choi SY, et al. Fermented Korean red ginseng extract enriched in Rd and Rg3 protects against non-alcoholic fatty liver disease through regulation of mTORC1. Nutrients 2019;11(12).
  30. Li G, et al. Ginsenoside Rg1 exerts anti-apoptotic effects on non-alcoholic fatty liver cells by downregulating the expression of SGPL1. Mol Med Rep 2022;25(5).
  31. Gu D, et al. Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease. Life Sci 2021;267:118986.
  32. Qi R, et al. Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor. Life Sci 2020;254:117776.
  33. Xu Y, et al. Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. Biol Pharm Bull 2018;41(11):1638-44. https://doi.org/10.1248/bpb.b18-00132
  34. Lee SM, et al. Characterization of Korean red ginseng (Panax ginseng meyer): history, preparation method, and chemical composition. J Ginseng Res 2015;39(4):384-91. https://doi.org/10.1016/j.jgr.2015.04.009
  35. Jiang S, et al. Peroxisomal fitness: a potential protective mechanism of fenofibrate against high fat diet-induced non-alcoholic fatty liver disease in mice. Diabetes Metab J 2022;46(6):829-42.
  36. Kim MS, et al. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver Int 2013;33(10):1583-93. https://doi.org/10.1111/liv.12287
  37. Chen XJ, et al. Ameliorative effects of Compound K and ginsenoside Rh1 on nonalcoholic fatty liver disease in rats. Sci Rep 2017;7:41144.
  38. Piao X, et al. Advances in saponin diversity of Panax ginseng. Molecules 2020;25(15).
  39. Huang Q, et al. Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of Sirt1 and activation of AMPK. Int J Mol Sci 2017;18(5).
  40. Liu CY, et al. Preparation of minor ginsenosides C-Mc, C-Y, F2, and C-K from American ginseng PPD-ginsenoside using special ginsenosidase type-I from Aspergillus Niger g.848. J Ginseng Res 2015;39(3):221-9. https://doi.org/10.1016/j.jgr.2014.12.003
  41. Roh E, et al. Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress. J Ethnopharmacol 2020;259:112927.
  42. Jeong H, et al. Beneficial effects of Korean red ginseng in the progression of nonalcoholic steatohepatitis via FABP4 modulation. Am J Chin Med 2018:1-27.
  43. Yang D, et al. Oral administration of Jinan Red Ginseng and licorice extract mixtures ameliorates nonalcoholic steatohepatitis by modulating lipogenesis. J Ginseng Res 2022;46(1):126-37. https://doi.org/10.1016/j.jgr.2021.05.006
  44. Wei W, et al. Black ginseng protects against Western diet-induced nonalcoholic steatohepatitis by modulating the TLR4/NF-kappaB signaling pathway in mice. J Food Biochem 2022;46(12):e14432.
  45. Choi N, et al. Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model. J Ginseng Res 2019;43(2):196-208. https://doi.org/10.1016/j.jgr.2017.10.002
  46. Lu B, et al. 20(S)-Protopanaxatriol ameliorates MAFLD by inhibiting NLRP3 inflammasome. Eur J Pharmacol 2023;940:175468.
  47. Hyun SH, et al. Physiological and pharmacological features of the non-saponin components in Korean Red Ginseng. J Ginseng Res 2020;44(4):527-37. https://doi.org/10.1016/j.jgr.2020.01.005
  48. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2009;55:1-99.